Eyebot Raises $20M to Scale 90-Second Vision Test and Doctor-Verified Prescriptions

Eyebot, the company behind the 90-second vision test kiosk that delivers doctor-verified glasses prescriptions, announced it has raised $20 million in Series A funding. The round was led by General Catalyst with participation from returning investors AlleyCorp, Baukunst, Village Global, and Ubiquity Ventures. The company is redefining how people access vision care by removing traditional barriers such as appointment delays, insurance hurdles, and limited accessibility. Its kiosks, now located in malls, universities, retail stores, and grocery chains, provide a free, 90-second vision test that can generate a glasses prescription reviewed and verified by licensed eye doctors.

Since its seed round last year, Eyebot has delivered more than 45,000 free vision tests during its pilot phase and is on track to exceed half a million annually. With this new funding, the company plans to expand across hundreds of new retail locations, scale its clinical and engineering teams, and deepen its engagement with eye care professionals. “Clear vision shouldn’t require months of waiting, high costs, or geographic luck,” said Matthias Hofmann, co-founder and CEO of Eyebot. “This funding allows us to accelerate our expansion, strengthen our clinical partnerships, and bring accessible vision care to millions more people.”

Eyebot aims to enhance the in-person optical journey by making convenient, high-quality vision tests available in everyday settings such as malls, pharmacies, grocery stores, schools, and private practices. Several high-profile launches with leading retail partners are planned later this year to drive nationwide adoption. While Eyebot increases access, it is not replacing doctors but empowering them. Every prescription is reviewed by a licensed clinician to ensure safety and quality, and the company has conducted more than 2,500 IRB-approved patient studies showing accuracy on par with traditional in-person exams. Doctor-reviewed prescriptions from Eyebot consistently achieve higher satisfaction scores than the industry average.

To reinforce its doctor-led approach, Eyebot has created a Clinical Advisory Board chaired by Chief Medical Officer Dr. Alexander Martin and composed of leaders from both optometry and ophthalmology, who will guide clinical oversight as the company scales nationwide. The need is significant: more than 3 million people in the United States live with vision impairment, and 8 million more are affected by uncorrected refractive errors such as nearsightedness. Many delay or avoid care because of cost, long wait times, or lack of nearby providers. Eyebot addresses this gap by placing vision testing where people already are, enabling retailers to expand services with minimal footprint, supporting online eyewear brands as they move into physical storefronts, and helping established brick-and-mortar locations boost their capacity. The result is a new, scalable model for delivering affordable, doctor-supervised vision care across the country.